Curcumin for gastritis, atrophic

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 26 May 2016: Trial registered, NCT02782949
  2. 4 Apr 2017: Trial started, NCT02782949

The trials

NCT02782949: Curcumin in Preventing Gastric Cancer in Patients With Chronic Atrophic Gastritis or Gastric Intestinal Metaplasia

State
Under way
Phase
Phase 2
People
50 taking part
Started
4 Apr 2017
Primary completion
6 Oct 2022
Arms
Arm I (curcumin)
Results
Posted on the registry
  1. 26 May 2016: Trial registered
  2. 4 Apr 2017: Trial started
  3. 5 Mar 2024: Trial results posted

Posted results

The numbers the trial's sponsor posted to the registry, as written there. The registry record says what each measure runs from and to.

Absolute Change in IL-1beta Cytokine Levels in the Gastric Mucosa

Primary outcome · Median, pg/mL · Baseline up to 6 months

GroupAnalysedValue
Arm I (Curcumin)
Antrum: IL-1beta Difference
220.0 (Full Range -4.2 to 10.9)
Arm II (Placebo)
Antrum: IL-1beta Difference
25-0.1 (Full Range -5.5 to 4.1)
Arm I (Curcumin)
Body: IL-1beta Difference
220.0 (Full Range -5.2 to 4.2)
Arm II (Placebo)
Body: IL-1beta Difference
250.1 (Full Range -0.8 to 8.6)
  • p = 0.3990, Wilcoxon Rank-Sum test (superiority test). Posted for: Arm I (Curcumin), Arm II (Placebo)

Change in Histology Gastric Score

Secondary outcome · Median, scores on a scale · Baseline up to 6 months

GroupAnalysedValue
Arm I (Curcumin)
Correa Score Difference (Puerto Rico data) central review
220.0 (Full Range -2.8 to 3.6)
Arm II (Placebo)
Correa Score Difference (Puerto Rico data) central review
250.0 (Full Range -3.6 to 2.6)
Arm I (Curcumin)
Correa Score Difference (UAB data)
220.0 (Full Range -3.6 to 3.6)
Arm II (Placebo)
Correa Score Difference (UAB data)
250.0 (Full Range -3.9 to 3.5)

Additional Gastric Mucosal Cytokine/Chemokine Levels (TNFalpha, and IP-10)

Secondary outcome · Median, pg/mL · Baseline up to 6 months

GroupAnalysedValue
Arm I (Curcumin)
Antrum: TNF-alpha Difference
22-0.1 (Full Range -3.8 to 5.7)
Arm II (Placebo)
Antrum: TNF-alpha Difference
250.0 (Full Range -1.8 to 8.7)
Arm I (Curcumin)
Antrum: IP-10 Difference
228.0 (Full Range -135.7 to 285.9)
Arm II (Placebo)
Antrum: IP-10 Difference
2514.3 (Full Range -218.3 to 179.2)
Arm I (Curcumin)
Body: IP-10 Difference
221.2 (Full Range -356.5 to 217.0)
Arm II (Placebo)
Body: IP-10 Difference
255.2 (Full Range -132.3 to 157.9)
Arm I (Curcumin)
Body: TNF-alpha Difference
220.0 (Full Range -1.8 to 4.6)
Arm II (Placebo)
Body: TNF-alpha Difference
250.0 (Full Range -8.0 to 12.0)
Arm I (Curcumin)
Antrum: IL-8 Difference
22-0.3 (Full Range -30.7 to 12.4)
Arm II (Placebo)
Antrum: IL-8 Difference
25-0.2 (Full Range -55.4 to 385.2)
Arm I (Curcumin)
Body: IL-8 Difference
220.0 (Full Range -1.8 to 4.6)
Arm II (Placebo)
Body: IL-8 Difference
250.0 (Full Range -8.0 to 12.0)

Gastric Mucosal Deoxyribonucleic Acid (DNA) Damage

Secondary outcome · Number of participants · Baseline up to 6 months

GroupAnalysedValue
Arm I (Curcumin)
DNA Damage: Baseline, < 1%
2218
Arm II (Placebo)
DNA Damage: Baseline, < 1%
2519
Arm I (Curcumin)
DNA Damage: Baseline, 1-5%
222
Arm II (Placebo)
DNA Damage: Baseline, 1-5%
254
Arm I (Curcumin)
DNA Damage: Baseline, >5%
222
Arm II (Placebo)
DNA Damage: Baseline, >5%
251
Arm I (Curcumin)
DNA Damage: Baseline, Missing
220
Arm II (Placebo)
DNA Damage: Baseline, Missing
251
Arm I (Curcumin)
DNA Damage: Month 6, < 1%
2219
Arm II (Placebo)
DNA Damage: Month 6, < 1%
2513
Arm I (Curcumin)
DNA Damage: Month 6, 1-5%
222
Arm II (Placebo)
DNA Damage: Month 6, 1-5%
2510
Arm I (Curcumin)
DNA Damage: Month 6, >5%
221
Arm II (Placebo)
DNA Damage: Month 6, >5%
251
Arm I (Curcumin)
DNA Damage: Month 6, Missing
220
Arm II (Placebo)
DNA Damage: Month 6, Missing
251
  • p = 0.74, Fisher Exact (superiority test). Posted for: Arm I (Curcumin), Arm II (Placebo)

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.